Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medios AGMEDOF 88 EV-to-EBIT is 9.10 as of Jul. 16, 2026, which is 35% below its 10-year median of 14.05. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $68.42. The stock has 2 warning signs investors should review. Among 93 Medical Distribution companies, Medios AG ranks better than 59.14% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medios AG's Enterprise Value for the quarter that ended in Mar. 2026 was $1,167 Mil.
Medios AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medios AG EV-to-EBIT Related Terms
Medios AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medios AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medios AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medios AG's EV-to-EBIT falls into.
Medios AG's current Enterprise Value is $474 Mil.
Medios AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medios AG (MEDOF) has a EV-to-EBIT of 9.10 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medios AG and its competitors. This is 35% below median its historical median of 14.05. Over the past decade, Medios AG's EV-to-EBIT has ranged from 4.48 to 72.37. According to the industry distribution chart, Medios AG ranks #38 out of 93 companies in the Medical Distribution industry, placing it in the top 40.9%.
Is Medios AG's EV-to-EBIT too high?
Medios AG's current EV-to-EBIT of 9.10 is 35% below median its 10-year median of 14.05. Over the past 10 years, this metric has ranged from a low of 4.48 to a high of 72.37. The Medical Distribution industry median EV-to-EBIT is 11.77. Medios AG's value of 9.10 is 22.7% below this industry median. Based on the distribution chart, Medios AG ranks #38 out of 93 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's EV-to-EBIT compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medios AG ranks #38 out of 93 companies for EV-to-EBIT. This puts Medios AG in the upper half of its industry. The industry median EV-to-EBIT is 11.77. Medios AG's value of 9.10 is 22.7% below this benchmark. Historically, Medios AG's own EV-to-EBIT has ranged from 4.48 to 72.37 over the past decade. While the company's 10-year median is 14.05 vs. the industry median of 11.77, Medios AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.77, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medios AG's current EV-to-EBIT of 9.10 is 22.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medios AG and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current EV-to-EBIT is 9.10, which is 35% below median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current EV-to-EBIT of 9.10. The stock's GF Value™ is $68.42, compared to a current price of $50.00 — trading 26.9% below its estimated fair value. The current EV-to-EBIT is 9.10, which is 35% below median its 10-year median of 14.05 and 22.7% below the Medical Distribution industry median of 11.77. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medios AG (MEDOF), the current EV-to-EBIT is 9.10 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 26.9% below its estimated GF Value™ of $68.42.
Key valuation signals for MEDOF:
EV-to-EBIT: 9.10 (35% below median its 10-year median of 14.05)
GF Value™: $68.42 vs. price of $50.00 (26.9% below fair value)
Industry Position: 22.7% below the Medical Distribution median (#38 of 93)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
